Partnering & Licensing Opportunities

Arbutus has an industry-leading position to transform the treatment of hepatitis B and address the HBV global market opportunity. Our commitment to curing HBV is reinforced by our unique and exclusive partnership, with the Baruch S. Blumberg Institute, one of the world’s leading research institutes dedicated to curing HBV.

 

Our goal is to cure HBV and we believe that combination therapy will be required to achieve complete eradication of HBV from the liver. Our pipeline currently has eight unique products targeting HBV, but we continue to gather the best ideas and explore leading edge science to broaden our approach. As such, we are interested in exploring external opportunities for novel therapeutics targeting the three pillars of HBV persistence – viral suppression, simulation/reactivation of the suppressed immune system, and elimination of cccDNA. In addition to this, we have active collaborations with several leading pharmaceutical companies and research institutes focusing on RNAi and our LNP Technology. Our RNAi partnering objectives include:

  • Providing complete RNAi Research and Discovery capability to companies looking to enter the RNAi space.
  • Partnering our delivery technology to enable companies with other RNA trigger technology (e.g. siRNA, miRNA, mRNA) to advance their therapeutics programs.
  • Finding regional and strategic partners for our development programs.

Why Arbutus?

We are dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

 

We are also developing a pipeline of Non-HBV Assets that leverage our expertise in RNAi therapeutics and leading LNP Technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body’s own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. To date, eight LNP products have entered clinical development and more than 250 patients have been administered RNAi therapeutics using Arbutus’ LNP technology.

 

Our LNP is broadly applicable to many therapeutic areas because it can incorporate a variety of different types of RNA triggers, such as siRNA, miRNA, and mRNA. We also have extensive experience, either directly or through our partners, in manufacturing LNP formulated products, and in preparing the appropriate CMC documentation for regulatory authorities worldwide.

 

We have a portfolio of assets combining multiple technologies, a robust pipeline of near-term catalysts with long-term value creation potential, and a proven management team and scientific leadership in antiviral and RNAi drug discovery and development. Add to this, Arbutus has a broad Intellectual Property portfolio for its products and delivery technology which provides an excellent level of protection for any formulated products.

 

If you are interested in collaborating with Arbutus, please contact our business development team at bd@arbutusbio.com.